| Literature DB >> 28725256 |
Ichiro Yasuhi1, Tomoko Soda1, Hiroshi Yamashita1, Atsuko Urakawa1, Mihoko Izumi1, Yukari Kugishima1, Yasushi Umezaki1.
Abstract
BACKGROUND: Although breastfeeding is expected to reduce the incidence of diabetes in women with gestational diabetes, the effect has not been clearly confirmed. We examined whether or not high-intensity breastfeeding reduces the incidence of abnormal glucose tolerance and investigated the effect of high-intensity breastfeeding on insulin resistance during the first year postpartum in Japanese women with current gestational diabetes.Entities:
Keywords: Abnormal glucose tolerance; Breastfeeding; Gestational diabetes; Insulin resistance; Postpartum
Year: 2017 PMID: 28725256 PMCID: PMC5513345 DOI: 10.1186/s13006-017-0123-z
Source DB: PubMed Journal: Int Breastfeed J ISSN: 1746-4358 Impact factor: 3.461
Characteristics of the participants (n = 88)
| Mean ± SD or number (%) | Range | |
|---|---|---|
| Age (years) | 33.3 ± 4.9 | 20-43 |
| Primipara | 46 (52.3%) | |
| Stature (cm) | 158 ± 5 | 147-172 |
| Prepregnancy weight (kg) | 58.5 ± 12.6 | 40-90 |
| Prepregnancy BMI (kg/m2) | 23.9 ± 5.1 | 16.6-38.9 |
| Family history of diabetes | 46 (52.2%) | |
| OGTT results | ||
| Fasting plasma glucose (mg/dl) | 86.1 ± 10.5 | 68-118 |
| 1-h plasma glucose (mg/dl) | 188.2 ± 23.8 | 95-266 |
| 2-h plasma glucose (mg/dl) | 158.2 ± 25.7 | 86-232 |
| Women diagnosed by the Japanese criteria | 23 (26.1%) | |
| Fasting insulin (mU/L) | 7.3 ± 3.4 | 2.2-18.6 |
| Insulin therapy during pregnancy | 54 (61.3%) | |
| Weight gain during pregnancy (kg) | 6.9 ± 5.3 | −11.2-20.4 |
| Gestational age at delivery | 38.5 ± 2.7 | 29-42 |
| Cesarean birth | 26 (29.5%) | |
| Birthweight (g) | 2922 ± 594 | 910-4090 |
BMI body mass index, OGTT oral glucose tolerance test, SD standard deviation
Fig. 1High-intensity breastfeeding and the development of abnormal glucose tolerance during the first year (up to 14 months) postpartum. P value was from the chi-squared test
The protective effect of high-intensity breastfeeding against the development of abnormal glucose tolerance during the first year (up to 14 months) postpartum
| Crude OR | 95%CI |
| Model Ia | Model IIb | |||||
|---|---|---|---|---|---|---|---|---|---|
| Adjusted OR | 95% CI |
| Adjusted OR | 95% CI |
| ||||
| High- intensity breast- feeding | 0.24 | 0.06, 0.75 | 0.013 | 0.18 | 0.039, 0.64 | 0.0077 | 0.20 | 0.040, 0.80 | 0.022 |
The reference of OR was the abnormal glucose tolerance prevalence in non-high-intensity breastfeeding women
OR odds ratio, CI confidence interval, BMI body mass index, OGTT oral glucose tolerance test
aAdjusted for prepregnancy BMI and 2-h plasma glucose at the diagnostic OGTT during pregnancy
bAdjusted for age, prepregnancy BMI, family history of diabetes, 2-h plasma glucose at diagnostic OGTT during pregnancy, diagnostic criteria, weight gain during pregnancy and weight change during postpartum
Fig. 2Duration of high-intensity breastfeeding and the development of abnormal glucose tolerance during the first year (up to 14 months) postpartum. ¶ Group 1: women who met the high-intensity breastfeeding definition only for 6-8 weeks and not at 6 months postpartum. § Group 2: women with high-intensity breastfeeding at 6 months but not at 12 months postpartum. † Group 3: women still engaging in high-intensity breastfeeding at 12 months postpartum. P values were from the chi-squared test
The protective effect of the duration of high-intensity breastfeeding against the development of abnormal glucose tolerance during the first year (up to 14 months) postpartum
| High- intensity breastfeeding groups | Crude OR | 95% CI |
| Model Id | Model IIe | ||||
|---|---|---|---|---|---|---|---|---|---|
| Adjusted OR | 95% CI |
| Adjusted OR | 95% CI |
| ||||
| Group 1a | 0.29 | 0.057, 1.27 | 0.10 | 0.20 | 0.032, 1.06 | 0.057 | 0.25 | 0.036, 1.44 | 0.12 |
| Group 2b | 0.22 | 0.046, 0.93 | 0.040 | 0.20 | 0.033, 0.98 | 0.048 | 0.15 | 0.022, 0.89 | 0.036 |
| Group 3c | 0.23 | 0.058, 0.78 | 0.017 | 0.16 | 0.032, 0.64 | 0.008 | 0.15 | 0.029, 0.63 | 0.0084 |
The reference of OR was the abnormal glucose tolerance prevalence in non-high-intensity breastfeeding women
OR odds ratio, CI confidence interval, BMI body mass index, OGTT oral glucose tolerance test
aGroup 1: women who met the high-intensity breastfeeding definition only for 6-8 weeks and not at 6 months postpartum (n = 14)
bGroup 2: women with high-intensity breastfeeding at 6 months but not at 12 months postpartum (n = 16)
cGroup 3: women still engaging in high-intensity breastfeeding at 12 months postpartum (n = 40)
dAdjusted for prepregnancy BMI and 2-h plasma glucose at the diagnostic OGTT during pregnancy
eAdjusted for age, prepregnancy BMI, family history of diabetes, 2-h plasma glucose at diagnostic OGTT during pregnancy, diagnostic criteria, weight gain during pregnancy and weight change during postpartum
Comparison of metabolic parameters between women with and without high-intensity breastfeeding at each postpartum visit
| Women with high-intensity breastfeeding | Women without high-intensity breastfeeding |
| Adjusted * | Adjusted ** | |
|---|---|---|---|---|---|
| At 6-8 weeks postpartum | |||||
| Number of participants (%) | 69 (79%) | 18 (21%) | |||
| BMI | 22.5 ± 4.3 | 24.4 ± 3.5 | 0.081 | 0.59 | 0.43 |
| Fasting plasma glucose | 87.3 ± 9.9 | 92.8 ± 9.0 | 0.036 | 0.13 | 0.18 |
| Fasting insulin | 5.1 ± 4.1 | 6.3 ± 3.0 | 0.24 | 0.85 | 0.67 |
| HOMA-IR | 1.12 ± 0.97 | 1.45 ± 0.73 | 0.18 | 0.74 | 0.60 |
| Disposition index | 3.89 ± 2.09 | 3.84 ± 3.05 | 0.94 | 0.21 | 0.81 |
| At 6-8 months postpartum | |||||
| Number of participants (%) | 52 (63%) | 31 (37%) | |||
| BMI | 21.6 ± 3.9 | 24.3 ± 5.6 | 0.0097 | 0.16 | 0.27 |
| Fasting plasma glucose | 91.3 ± 11.5 | 98.7 ± 12.5 | 0.0071 | 0.033 | 0.013 |
| Fasting insulin | 5.0 ± 2.3 | 8.2 ± 5.0 | 0.0001 | 0.0012 | 0.0002 |
| HOMA-IR | 1.16 ± 0.65 | 2.06 ± 1.33 | <0.0001 | <0.0001 | <0.0001 |
| Disposition index | 3.59 ± 3.12 | 3.06 ± 2.66 | 0.43 | 0.57 | 0.37 |
| At 12-14 months postpartum | |||||
| Number of participants (%) | 35 (46%) | 42 (54%) | |||
| BMI | 21.8 ± 4.2 | 23.9 ± 5.6 | 0.082 | 0.046 | 0.15 |
| Fasting plasma glucose | 91.2 ± 8.4 | 96.9 ± 10.9 | 0.013 | 0.045 | 0.032 |
| Fasting insulin | 5.4 ± 2.7 | 7.7 ± 4.7 | 0.013 | 0.028 | 0.045 |
| HOMA-IR | 1.24 ± 0.68 | 1.88 ± 1.26 | 0.0081 | 0.021 | 0.030 |
| Disposition index | 3.45 ± 3.05 | 3.79 ± 3.61 | 0.65 | 0.45 | 0.98 |
The breastfeeding condition at each visit was defined as the condition at the time of the visit. For example, breastfeeding women at the second (6 months) visit included women who had lactated for 6 months as well as (eventually) 12 months postpartum. Similarly, non-breastfeeding women at the second (6 months) visit included always non-breastfeeding women as well as women who had lactated for 6-8 weeks postpartum but did not continue to breastfeed through 6 months postpartum
BMI body mass index, NS not significant, HOMA-IR homeostasis model of assessment of insulin resistance, OGTT oral glucose tolerance test
*Adjusted for prepregnancy BMI and 2-h plasma glucose at the diagnostic OGTT during pregnancy
**Adjusted for age, prepregnancy BMI, family history of diabetes, 2-h plasma glucose at diagnostic OGTT during pregnancy, diagnostic criteria, weight gain during pregnancy and weight change during postpartum
Fig. 3Duration of high-intensity breastfeeding and the HOMA-IR at 12-14 months postpartum. ¶ Group 1: women who met the high-intensity breastfeeding definition only for 6-8 weeks and not at 6 months postpartum. § Group 2: women with high-intensity breastfeeding at 6 months but not at 12 months postpartum. † Group 3: women still engaging in high-intensity breastfeeding at 12 months postpartum Data were presented as the mean ± SD. P values were from Student’s t-test. SD, standard deviation; HOMA-IR, homeostasis model of assessment of insulin resistance